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Background: In patients with advanced (stage IIIb/IV) NSCLC, the
addition of cetuximab to chemotherapy has demonstrated increased
activity compared with chemotherapy alone. Furthermore, the addi-
tio of cetuximab to RT in patients with locally advanced squamous
cell head & neck carcinoma significantly prolongs the duration of
locoregional control and median overall survival compared to ra-
diotherapy alone. Therefore, the SCRATCH study was designed to
assess the safety of synchronous cetuximab with radical RT in
patients with Stage III NSCLC. The safety results of cohort 1 from
this phase I study are presented below.
Methods: Twelve patients with inoperable stage III NSCLC were
enrolled into cohort I. Inclusion criteria were performance status
0–1, adequate organ function, and disease encompassable within a
radical RT volume. Exclusion criteria were previous malignancy,
thoracic RT or treatment with EGFR (epidermal growth factor
receptor) targeted therapy. Patients received platinum-based induc-
tion chemotherapy, followed by weekly intravenous cetuximab (ini-
tial dose 400mg/m2; maintenance dose 250mg/m2) and concomitant
Rt (64Gy/32fractions/45days). The primary end-point was toxicity.
NCI Common Toxicity Criteria (CTC) V3.0 assessments were
preformed weekly during radiotherapy, and at regular follow-up
visits.
Results: 9 out of 12 patients coompleted the concomitant therapy as
planned, with no dose reductions. 3 patients did not complete the full
schedule. One died from bronchopneumonia mid-treatment; one
experienced grade 3 lethargy following the first cetuximab dose and
declined further cetuximab; one experienced a grade 2 skin reaction
following the third dose of cetuximab and declined futher treatment.
On follow-up only one patient has developed a grade III reaction –
pneumonitis – which settled on steroids with intermittent oxygen.
Three patients have died on follow-up (2 from disease progression
and one from thromboembolic disease). Of the 12 patients entered
ito the study, 8 have survived at least 1 year, measured from the first
day of induction chemotherapy.
Conclusion: The results suggest that the early and late toxicities of
synchronous cetuximab and radical RT are acceptable.
(J Thorac Oncol. 2008;3: 648–651)
A consensus has yet to be reached regarding the optimaltreatment for inoperable stage III non-small cell lung
cancer (NSCLC). The use of combined modality chemother-
apy and radiotherapy has been demonstrated to confer a small
but significant survival advantage over radiotherapy alone.1
However, controversy still exists regarding whether the
treatments should be delivered sequentially or concomi-
tantly.2 Individual phase III randomized trials may have
demonstrated a median survival benefit of 3 to 14 weeks in
favor for synchronous delivery, but this has been at the
expense of increased toxicity.3–5 This is the rationale
behind investigating the safety and ultimately efficacy of
combining alternative, potentially less toxic, agents with
radiotherapy.
The epidermal growth factor receptor (EGFR) is com-
monly over-expressed or mutated in NSCLC cells.6 Ligand
binding can result in cell proliferation, invasion, angiogenesis
and the inhibition of apoptosis.7–9 Cetuximab (Erbitux/IMC-
C225) is a human-murine chimeric IgG1 monoclonal anti-
body that binds to the extracellular region of the EGFR and
acts as a competitive antagonist. It stimulates EGFR internal-
ization and can promote antibody-dependent cellular cytotox-
icity. Concomitant cetuximab and radiotherapy have been
shown to increase local control and survival in patients with
locally advanced squamous cell carcinoma of the head and
neck, compared with radiotherapy alone,10 with minimal
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additional toxicity. Cetuximab also has modest single-agent
activity in NSCLC, and when compared with first line che-
motherapy alone, superior response rates have been seen with
cetuximab in combination with both cisplatin and vinorel-
bine,11 and carboplatin plus paclitaxel.12
The aim of the SCRATCH pilot study is to assess the
safety of synchronous cetuximab and radical radiotherapy in
the treatment of stage III NSCLC.
PATIENTS AND METHODS
Study Design
This was a small prospective study designed to assess
the safety of concomitant cetuximab and radical radiotherapy
in 12 patients with stage III NSCLC. Initially a single center
study, it was later expanded into a dual center study. The
primary end-points were the incidence and grade of pneumo-
nitis, oesophagitis, dermatitis, hematological and other non-
hematological toxicities. The secondary end-points included
an assessment of overall survival, progression free survival,
and the response to treatment. The stopping criteria were the
occurrence of 4 or more of the following dose-limiting
toxicities: grade 3 or 4 pneumonitis/oesophagitis; grade 4
dermatitis/hematological toxicity/other systemic toxicity.
Patient Population
Trial entry was open to patients with inoperable Stage
III NSCLC. All patients were aged 18 years and had a
WHO performance status of 0 or 1. Eligibility requirements
also included adequate respiratory function tests; hematolog-
ical and biochemical parameters (including renal function);
and for women of childbearing potential, a negative preg-
nancy test and adequate contraceptive precautions were nec-
essary. Exclusion criteria were a pleural effusion, previous
malignancy, prior thoracic radiotherapy, prior therapy with
EGFR targeted therapy, any severe unstable concurrent med-
ical illness likely to interfere with the study protocol, and
pregnancy or breast-feeding. Informed, written consent was
obtained from each patient, and the protocol and consent
process were reviewed by the Ethics Committee based at St.
Thomas’ Hospital, London, UK.
Treatment Plan
Potentially eligible patients received up to 4 cycles of
platinum-based induction chemotherapy before having a re-
peat computed tomography (CT) scan to assess response.
Those whose disease was inoperable but still treatable with
radical radiotherapy were offered entry into the study.
Radiotherapy treatment was planned to start 4 weeks
from the end of the induction chemotherapy. All patients
were treated with conformal plans based on 3-dimensional
CT outlines and plans. A total dose of 64 Gy in 32 fractions
was delivered to the tumor in two phases. The clinical target
volume for phase one included the gross tumor volume as
defined by CT and positron emission tomography and any
lymph nodes considered to be at high risk of micrometastatic
disease (ipsilateral hilar and ipsilateral mediastinal lymph
nodes in patients with bulky paramediastinal tumors or
tumors invading the mediastinum). A margin of 1 to 1.5
cm was added to give the planning target volume (PTV)
for phase one. This received 50 Gy in 25 fractions using 6
MV photons. For phase 2 the clinical target volume com-
prised the gross tumor volume only. A margin of 1 to 1.5
cm was added to give the PTV for phase two. This received
a dose of 14 Gy in 7 fractions using 6 MV photons. Dose
volume histograms were obtained for the PTV, lungs
minus PTV, spinal cord and esophagus. The maximum
point dose to the spinal cord was limited to 50 Gy, and the
volume of the lungs minus the PTV receiving 20 Gy or
more (V20) was limited to 30%.
A 400 mg/m2 initial dose of cetuximab was adminis-
tered intravenously 1 week before starting radiotherapy. This
was given as a 2 hour infusion with premedication (10 mg iv
chlorpheniramine, 1 g po paracetamol). Subsequent weekly
doses of cetuximab were administered intravenously at a dose
of 250 mg/m2. These were given over 1 hour, again with
premedication (10 mg iv chlorpheniramine, 1 g po paraceta-
mol). The cetuximab therapy was continued until the end of
the radiotherapy course. This regimen was similar to that
used by Bonner et al.10 in the head and neck trials.
TABLE 1. Patient Characteristics at Enrolment
Characteristic Value
Age (yr)
Median 67.5
Range 58–76
Sex
Male 9
Female 3
WHO performance status
0 5
1 7
Histology
Adenocarcinoma 4
Squamous cell carcinoma 6
Large cell carcinoma 1
Nonspecified NSCLC 1
Stage
IIIa 4
IIIb 6
IV 2
Induction chemotherapy
Gemcitabine/carboplatin 4
Vinorelbine/cisplatin 5
Vinorelbine/carboplatin 3
Number of chemotherapy cycles
2 1
3 9
4 2
MRC dyspnoea score
0 7
1 2
2 3
WHO, World Health Organization; NSCLL, non-small cell lung cancer; MRC,
Medical Research Council.
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Toxicity was assessed according to the National Cancer
Institute Common Toxicity Criteria (V3.0) and the Radiation
Therapy Oncology Group late toxicity index. Patient assess-
ments were made weekly during treatment, and then at
months 1, 2, 3, 5, 7, 10, 13, 16, 19, and on further follow-up.
RESULTS
From September 5, 2005 to March 2, 2007, 12 patients
were enrolled into the study. Their clinical characteristics are
shown in Table 1. Two of the patients were thought to have
stage III disease and incidental single adrenal adenomas at
presentation. On follow-up the adrenal lesions were found to
be metastases and so these patients are recorded as having
stage IV disease.
Eleven patients completed the planned radiotherapy
schedule. One patient died of bronchopneumonia mid treat-
ment having received 23 fractions. Two other patients
stopped receiving concomitant cetuximab early due to side
effects. All patients who completed treatment were followed
up and evaluated for toxicity.
Radiotherapy Details
Single phase treatments were delivered to eight pa-
tients, while four received 2 phase schedules. None of the 11
patients who completed their radiotherapy course experi-
enced a delay of more than 3 days during their schedule. The
median V20 (Lung volume minus PTV) value was 22%
(range, 14–29%). The radiotherapy details are summarized in
Table 2.
Cetuximab Details
All 12 patients received the initial dose of cetuximab 1
week before radiotherapy. One patient experienced grade 3
toxicity following this loading dose, and received no further
cetuximab. 11 patients went on to receive concomitant cetux-
imab therapy, with 9 completing the full schedule without
any dose reductions. The two patients who did not complete
the cetuximab schedule received 2 and 4 full dose concomi-
tant treatments.
Toxicity Data
The treatment toxicities are shown in Tables 3 and 4.
Table 3 shows the acute toxicities encountered during the
concomitant treatment. One patient died of bronchopneumo-
nia midway through their treatment having received 4 con-
comitant doses of cetuximab. They had received 4 cycles of
vinorelbine/carboplatin as induction chemotherapy. Another
patient experienced acute grade III toxicity. This was a
systemic reaction with severe fatigue following the initial
dose of the drug. No further cetuximab was given to this
patient. One further patient did not receive the full course of
cetuximab having developed a grade II skin reaction follow-
ing 2 concomitant doses and choosing to withdraw from the
TABLE 2. Radiotherapy Details
Radiotherapy Details Value
Basic details
Beam energy 6 MV
Number of beams 3
Shielding MLC
Dose 64 Gy
Fraction number 32
CTV to PTV margins (cm)
Cranio-caudal 1.5
Axially 1.0
Lung V20 (%)
Median 22
Range 14–29
CTV, clinical target volume; PTV, planning target volume.
TABLE 3. Toxicity During Radiotherapy: National Cancer Institute Common Toxicity Criteria
(V3.0)
Grade
Organ Toxicity (n  12)
Skin Rash Dyspnoea Oesophagitis Fatigue Infection Chest Pain Stomatitis
0 — 9 4 5 8 10 10
1 9 3 8 6 3 2 1
2 3 — — — — — 1
3 — — — 1 — — —
4 — — — — — — —
5 — — — — 1 — —
TABLE 4. Toxicity Post-Radiotherapy: RTOG Late Toxicity Index
Grade
Organ Toxicity late (n  11)
Skin Rash Pneumonitis Oesophagitis Fatigue Infection Chest Pain Stomatitis
0 5 5 8 6 9 10 11
1 6 2 3 4 2 1 —
2 — 3 — 1 — — —
3 — 1 — — — — —
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study. They were prescribed oxytetracycline, and the skin
reaction settled to grade1 within a week. The other 9 patients
all tolerated the concomitant therapy well.
Eleven patients have been followed up after completing
their treatment. Their late toxicity data is displayed in Table
4. The median postradiotherapy follow-up for these patients
is 10 months (range, 2–15 months). Three patients have died
during the follow-up period, 2 within 2 to 4 months following
radiotherapy. The early deaths were respectively due to
disease progression on treatment and recurrent thromboem-
bolic disease despite anticoagulation. The third patient died
of disease progression 19 months after starting treatment.
None of these deaths was attributed to treatment with cetux-
imab and radiotherapy. There has been one grade III toxicity
during the follow-up period–pneumonitis–which resolved
with steroids (and initially intermittent home oxygen).
Survival and Tumor Response
Eight patients are still alive and on follow up. Of the
four patients who died, their survival figures as measured
from the first day of induction chemotherapy are 4,6,13, and
19 months, respectively. Of the remaining patients, 5 have
survived over a year (range, 8–20 months). Ten patients had
a CT scan 2 months after completion of RT. Three patients
had progressive disease–1 locally and 2 in adrenal lesions
thought initially to be adenomas. Of these latter two patients
both had partial local responses. The remaining seven pa-
tients all had partial radiologic responses to treatment.
DISCUSSION
Our data has demonstrated that the combination of
platinum-based induction chemotherapy followed by con-
comitant cetuximab and radical radiotherapy has acceptable
toxicity. This approach is attractive as it avoids the additional
toxicity from administering chemotherapy and radiotherapy
concurrently. However, this is a small study and further
studies need to be performed to assess both the safety and
efficacy of this approach.
ACKNOWLEDGMENTS
We thank Guy’s & St. Thomas’ NHS Trust for spon-
soring the study, and Jackie Pullen from the Guy’s & St.
Thomas’ NHS Trust Research and Development Department
for her assistance. S.H. is funded by the CRUK lung motion
project grant and the Jill Calloumanopolous charitable fund
from Guy’s & St. Thomas’ Charity.
REFERENCES
1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomised clinical trials. BMJ 1995;311:
899–909.
2. Rowell NP, O’Rourke NP. Concurrent chemoradiotherapy in non-small
cell lung cancer. Cochrane Database Syst Rev 2004; CD002140.
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent
versus sequential thoracic radiotherapy in combination with mitomycin,
vindesine, and cisplatin in unresectable stage III non-small cell lung
cancer. J Clin Oncol 1999;17:2692–2699.
4. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in
a phase III comparison of sequential vs concurrent chemo-radiation for
patients with unresected stage III non-small cell lung cancer: RTOG
9410. Proc Am Soc Clin Oncol 2003; abstract 2499.
5. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus
sequential chemoradiotherapy with cisplatin and vinorelbine in locally
advanced non-small cell lung cancer: a randomized study. Lung Cancer
2004;46:87–98.
6. Lee SM. Is EGFR expression important in non-small cell lung cancer?
Thorax 2006;61:98–99.
7. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phos-
phoinositide-regulated kinases: Kinase activation by phosphoinositide-
dependent phosphorylation. Annu Rev Biochem 1999;68:965–1014.
8. Engebraaten O, Bjerkvig R, Pedersen PH, et al. Effects of EGF, bFGF,
NGF and PDGF(bb) on cell proliferation, migration and invasive capa-
bilities of human brain-tumor biopsies in vitro. Int J Cancer 1993;53:
209–214.
9. Shibata T, Kawano T, Nagayasu H, et al. Enhancing effects of epidermal
growth factor on human squamous cell carcinoma motility and matrix
degradation but not growth. Tumour Biol 1996;17:168–175.
10. Bonner J, Harari P, Giralt J, et al. Radiotherapy plus cetuximab for
squamous-cell carcinoma of the head and neck. N Eng J Med 2006;354:
567–578.
11. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of
cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorel-
bine alone as first-line therapy in EGFR-expressing advanced non-small
cell lung cancer. Ann Oncol 2008;19:362–369.
12. Lynch TJ, Patel T, Dreisbach L, et al. A Randomized multicentre phase
III study of cetuximab (Erbitux) in combination with Taxane/Carbopla-
tin versus Taxane/Carboplatin alone as first-line treatment for patients
with advanced metastatic non-small cell lung cancer (NSCLC). J Tho-
racic Oncol 2007;2:S340.
Journal of Thoracic Oncology • Volume 3, Number 6, June 2008 Safety Study of Induction Chemotherapy
Copyright © 2008 by the International Association for the Study of Lung Cancer 651
